Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda’s Zasocitinib Logs Positive Results in Global PIII Psoriasis Trials
Takeda Pharmaceutical said on March 28 that its oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) reported detailed positive results from two global PIII trials in plaque psoriasis — keeping it on track to begin global regulatory filings from FY2026.…
To read the full story
Related Article
- Takeda’s TYK2 Inhibitor Scores PIII Win in Psoriasis Trials
December 19, 2025
BUSINESS
- Meiji Pharma Invests in Centivax to Support Vaccine R&D
March 31, 2026
- Takeda’s Zasocitinib Logs Positive Results in Global PIII Psoriasis Trials
March 31, 2026
- Ferring, Nippon Kayaku to Co-Promote Bladder Cancer Gene Therapy
March 31, 2026
- Mochida to Acquire Urece from Fuji Yakuhin for 13.5 Billion Yen
March 31, 2026
- Sumitomo Files Latuda for Pediatric Schizophrenia in Japan
March 31, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…